Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative hematopoietic stem cell transplantation for refractory metastatic or relapsed solid tumors
2012-002464-27Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in Nonhematologic neoplasms, breast cancer, renal cell carcinoma (RCC) and 9 more, sponsored by European Institute of Oncology. Primary endpoint: Donor engraftment at day +84. Started Dec 2023; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
Nonhematologic neoplasmsbreast cancerrenal cell carcinoma (RCC)apudoma (NET)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2012-002464-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002464-27.